The Society of Interventional Oncology (SIO) has today announced at the SIO (30 January—3 February, Las Vegas, USA) annual scientific meeting, the launch of the society’s second clinical trial, TRIBUTE: A Multicenter Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy.
The TRIBUTE study, a multimillion-dollar project, is also the second multi-industry supported clinical study to be executed by the society since its first announcement of the ACCLAIM trial in 2021.
The Tribute study is collectively supported by the study’s exclusive pioneer trial partner Varian, a Siemens Healthineers, the study’s catalyst trial partner, Stryker, and the study’s advocate trial partner, Boston Scientific.
This is the first prospective, multicentre study to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilisation) in adult patients treated with both percutaneous ablation and palliative radiation therapy (RT) for symptomatic, high-risk metastatic bone lesions. The study was collaboratively designed and developed with the partnership of radiation oncology, which SIO sees as a critical multidisciplinary partner to the success of the study.
The Tribute study clinical leadership will include Jack Jennings (Washington University School of Medicine, St. Louis, USA) Sean Tutton (University of California, San Diego, USA), Clifford Robinson (Washington University School of Medicine, St. Louis, USA) and James Urbanic (University of California, San Diego, USA). “The results from the Tribute trial have the potential to reshape treatment guidelines for metastatic bone disease. Research is the cornerstone of progress in interventional oncology, and SIO remains committed to driving ground-breaking efforts that elevate the impact of clinical research in our field,” said Jennings.
Percutaneous ablation and RT have different mechanisms of alleviating pain and causing tumour death that may work synergistically. Radiation therapy is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients. Percutaneous ablation, a minimally invasive therapy for painful metastatic bone disease, can be performed with thermal modalities (e.g., radiofrequency, microwave, cryoablation) and requires minimal recovery. “This approach combines the strengths of both percutaneous ablation and radiation therapy. By leveraging their complementary mechanisms, we can offer patients an effective and minimally invasive treatment option for pain relief and tumour management in metastatic bone disease,” said Tutton.
Muneeb Ahmed (Beth Israel Deaconess Medical Center, Boston, USA), president of the SIO commented: “The success of studies like Tribute are fuelled by strong, long-term collaborations with our multidisciplinary physician colleagues and dedicated industry partners. We deeply value the ongoing commitment of our industry partners, whose investment is vital to advancing these critical research areas. The Tribute study is not just a step forward—it’s a bold leap in SIO’s vision to further establish the interventional oncology specialty, setting an ambitious pace for the entire field to follow.”
The Tribute study is set to launch in 2025 with the enrolment of 120 subjects across sites in the USA.
